Amid apprehensions over the commercial rollout of Russian Covid-19 vaccine Sputnik V in India, Dr Reddy’s Laboratories has assured to strengthen the commercial roll-out of Sputnik V in the coming weeks.
In a statement, Dr Reddy's said, neither the ongoing soft commercial launch nor work towards its ramp-up in India have been put on hold.
The Sputnik V vaccine, which was the third vaccine to get approval in India, was soft launched on a pilot basis earlier on May 14. The nationwide soft launch of Sputnik V has been done in over 50 cities and towns across the country.
Meanwhile, the Gamaleya National Research Center of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF), who are behind the formulation of Sputnik V, on Monday said that individuals vaccinated with Sputnik V will be protected against the new variants of SARS-CoV-2, including the Delta variant, first detected in India.
Also watch | Delta strain 8 times less sensitive to Covid vaccine antibodies: study